-
Q&A: Combination OCA-Bezafibrate for PBC, with Cynthia Levy, MD
23 Nov 2023 19:24 GMT
… of combination OCA and bezafibrate compared to bezafibrate monotherapy on safety, … . The investigational OCA and bezafibrate combination therapy presents an opportunity … Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction …
-
Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction
16 Nov 2023 09:35 GMT
… showed combination obeticholic acid (OCA)-bezafibrate caused normalization of multiple biomarkers … combination of OCA and bezafibrate achieved biochemical remission including … of combination OCA and bezafibrate compared to bezafibrate monotherapy on safety, …
-
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver MeetingĀ® 2023
13 Nov 2023 13:00 GMT
… show combination of OCA + bezafibrate achieved biochemical remission (normalization of … -activated receptor (PPAR) agonist, bezafibrate, on multiple key serum biomarkers … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator- …
-
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
23 Jun 2023 06:45 GMT
… . About the Investigational OCA-bezafibrate Fixed-Dose Combination
Intercept is … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator-activated … the treatment of PBC. OCA-bezafibrate combination therapy is investigational; …
-
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
07 Jun 2023 11:00 GMT
… obeticholic acid (OCA) and bezafibrate vs. bezafibrate monotherapy on serum biomarkers in … arms:
bezafibrate 200 mg (B200)
bezafibrate 400 mg (B400)
bezafibrate 200 mg … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator- …
-
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
16 May 2023 21:00 GMT
… of obeticholic acid (OCA) and bezafibrate, a peroxisome proliferator-activated receptor … trials. About the Investigational OCA-Bezafibrate Fixed-Dose Combination
Intercept is … individuals with PBC. The OCA-bezafibrate combination is investigational; safety and …
-
Intercept Pharmaceuticals Gets Orphan Drug Status for OCA and Bezafibrate to Treat Primary Biliary Cholangitis
16 May 2023 21:58 GMT
… combination of obeticholic acid and bezafibrate to treat a rare bile … the combination of OCA and bezafibrate, the biopharmaceutical company said.
-
Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
27 Apr 2023 10:55 GMT
… . About the Investigational OCA-Bezafibrate Fixed-Dose Combination
Intercept is … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator-activated … the treatment of PBC. OCA-bezafibrate combination therapy is investigational; …
-
Intercept Announces First Patient Dosed In Phase 2 Study Of OCA And Bezafibrate For The Treatment Of Primary Biliary Cholangitis
11 May 2022 12:48 GMT
… combination therapy with OCA and bezafibrate for the treatment of … indication and Important Safety Information). Bezafibrate, a pan-peroxisome proliferator-activated … bilirubin while improving pruritus. OCA-bezafibrate combination therapy is investigational; …
-
First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis
11 May 2022 14:49 GMT
… of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of …